Sponsor content
194 result(s) found, displaying 21 to 30
-
Sep-2025Prescription medicine evaluationActive ingredient: tirzepatide.
-
Prescription medicine registrationActive ingredients: mirikizumab.
-
Australian Public Assessment Report (AusPAR)Kisunla (donanemab) has been approved for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia (early symptomatic Alzheimer’s disease) that have only one or no copies of the apolipoprotein E ε4 (ApoE ε4) gene.
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
Prescription medicine registrationActive ingredients: donanemab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled pen.
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd